- Home
- BBOT vs NAVI Comparison
BBOT vs NAVI Comparison
Compare BBOT & NAVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BBOT | NAVI |
|---|---|---|
| Founded | 2016 | 1973 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Bankers/Brokers/Service |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.1B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | BBOT | NAVI |
|---|---|---|
| Price | $12.33 | $12.94 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 6 |
| Target Price | ★ $23.80 | $13.83 |
| AVG Volume (30 Days) | 194.2K | ★ 970.8K |
| Earning Date | 11-12-2025 | 01-28-2026 |
| Dividend Yield | N/A | ★ 4.95% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $443,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.50 | $10.53 |
| 52 Week High | $14.87 | $16.07 |
Technical Indicators
Market Signals| Indicator | BBOT | NAVI |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 55.57 |
| Support Level | N/A | $12.89 |
| Resistance Level | N/A | $13.21 |
| Average True Range (ATR) | 0.00 | 0.32 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 59.57 |
Price Performance
Historical ComparisonAbout BBOT BridgeBio Oncology Therapeutics Inc.
BridgeBio Oncology Therapeutics Inc, formerly BridgeBio Oncology Therapeutics is a clinical-stage biotechnology company that aims to transform the lives of patients with cancers driven by RAS and PI3Ka, the two frequently mutated oncogenes.
About NAVI Navient Corporation
Navient Corp provides technology-enabled education finance solutions that simplify complex programs and help millions of people achieve success. The company operates its business in three segments: Federal Education Loans, Consumer Lending, and Business Processing. A majority of its revenue is generated from the Federal Education Loans segment, in which the company owns and manages the Federal Family Education Loan Program (FFELP) loans, generating revenue mainly in the form of net interest income. The Consumer Lending segment owns and manages private education loans and is the master servicer for these portfolios. Through its Earnest brand, the company also refinances and originates in-school private educational loans.